Frequency of hypotension after intravenous streptokinase in patients presenting with ST elevation myocardial infarction
DOI:
https://doi.org/10.55958/jcvd.v19i1.115Keywords:
ST-Segment Elevation Myocardial Infarction, Hypotension.Abstract
INTRODUCTION: One of the primary causes of death and disability worldwide is Acute Myocardial Infarction. Streptokinase is still widely used in many countries for its treatment, despite percutaneous advancements in the field. This study was conducted to appraise the incidence with which hypotension occurred by streptokinase in patients suffering from acute ST-elevation Myocardial Infarction (STEMI) due to the significance of this disease and the potential side effects of streptokinase to the patient. The purpose of this study was to ascertain the frequency of hypotension in patients presenting with ST Elevation Myocardial Infarction, who are being administered streptokinase.
METHODOLOGY: The study was conducted at the Emergency Department of Punjab Institute of Cardiology, Lahore from August 25, 2020 to February 25, 2021. A total 280 patients with STEMI were enrolled in the study. Electrocardiographic diagnosis of ST Elevation Myocardial Infarction was performed by a consultant cardiologist. Bedside echocardiography was also performed by a consultant cardiologist. Manual blood pressure recording of the patients was carried out every five minutes during administration of Streptokinase Injection and every hour and three hours after completion. Data was input and analysed using SPSS v25.0. To account for these impact modifiers, we stratified the data according to age, gender, diabetes status, family history, smoking status, and hypercholesterolemia. The chi-square analysis will be performed when the stratification process is complete. A p-value of 0.05 or below was taken to be of statistical significance.
RESULTS: A total of 280 patients with STEMI were selected for this study. There were 165(58.9%) males and 115(41.1%) females. Mean age was 38.46±9.81 year. Among 280 patients with STEMI, 39(13.9%) patients had hypotension.
CONCLUSION: Streptokinase, given intravenously, had lower incidence of cardiovascular complications like hypotension. A future with less illness burden may be possible if we take a more targeted approach to lowering the risks that contribute to it via health education and promotion.
References
McAloon CJ, Boylan LM, Hamborg T, Stallard N, Osman F, Lim PB, Hayat SA. The changing face of cardiovascular disease 2000–2012: An analysis of the world health organisation global health estimates data. Int J Cardiol. 2016;224:256-64.
Rentrop KP, Feit F. Reperfusion therapy for acute myocardial infarction: Concepts and controversies from inception to acceptance. Am Heart J. 2015;170(5):971-80.
Tourani S, Bashzar S, Nikfar S, Ravaghi H, Sadeghi M. Effectiveness of tenecteplase versus streptokinase in treatment of acute myocardial infarction: a meta-analysis. Tehran Univ Med J. 2018;76(6):380-7.
Ahmed F, Rahman MA, Ahmed M, Ananya KF, Alamgir MH, Rahman MM. Pharmaco-invasive therapy as a reperfusion strategy–a practical alternative of primary percutaneous coronary intervention. Invasive and Clinical Cardiology. 2019;1(1):45-53.
Aslanabadi N, Safaie N, Talebi F, Dousti S, Entezari-Maleki T. The streptokinase therapy complications and its associated risk factors in patients with acute ST elevation myocardial infarction. Iranian J Pharmaceutical Res. 2018;17(1):53.
Afzal S, Khan MA, Muhammad H, Ashraf A, Afzal M. Psychosocial risk factors of myocardial infarction and adverse effects of streptokinase in public sector hospitals. Pak J Med Sci. 2015;31(4):821.
Taheri L, Zargham-Boroujeni A, Jahromi MK, Charkhandaz M, Hojat M. Effect of streptokinase on reperfusion after acute myocardial infarction and its complications: an ex-post facto study. Global J Health Sci. 2015;7(4):184.
Bendary A, Tawfik WA, Mahrous M, Salem M. P6436 Fibrinolytic therapy in patients with ST-segment elevation myocardial infarction: Accelerated versus standard Streptokinase infusion regimen; a randomized clinical study. Eur Heart J. 2018;39(1):566-9.
He J, Li J, Wang Y, Hao P, Hua Q. Neutrophil-to-lymphocyte ratio (NLR) predicts mortality and adverse-outcomes after ST-segment elevation myocardial infarction in Chinese people. Int J Clin Exp Pathol. 2014;7(7):4045-56.
Rabijns A, DeRanter C, DeBondt HL. Three dimensional structure of streptokinase, a plasminogen activator with therapeutic potential. J Am Cardiol. 1997;4(5):357–360.
Bunker SJ, Colquhoun DM, Esler MD, Hickie IB, Hunt D, Jelinek VM. Stress and coronary heart disease: psychosocial risk factors. Med J Aust. 2003;178(6):272–276.
Kosti? T, Perisi? Z, Mili? D, Apostolovi? S, Martinovi? SS, Bozinovi? N, et al. Coronary flow and hemorrhagic complications after alteplase and streptokinase administration in patients with acute myocardial infarction. Vojnosanit Pregl. 2009;66:218–222.
Mayer G, Story WE, Seco JE, Nocero MA, Jr, Shaskey DJ, Black MA. Intravenous streptokinase in acute myocardial infarction. Ann Emerg Med. 1985;14(5):410–415.
Devi P, Kamath DY, Anthony N, Santosh S, Dias B. Patterns, predictors and preventability of adverse drug reactions in the coronary care unit of a tertiary care hospital. Eur J Clin Pharmacol. 2012;68:427–33.
Mohebbi N, Shalviri G, Salarifar M, Salamzadeh J, Gholami K. Adverse drug reactions induced by cardiovascular drugs in cardiovascular care unit patients. Pharmacoepidemiol. Drug Saf. 2010;19:889–94.
